NCT05068206 - A Clinical Study to Compare the Efficacy and Safety of AK105 Plus Anlotinib and Capecitabine/Oxaliplatin (CapeOx) , Anlotinib Plus CapeOx, Bevacizumab Plus CapeOx | Biotech Hunter

Enrollment

120

Participants

Timeline

Start Date

October 8, 2021

Primary Completion Date

December 31, 2023

Study Completion Date

June 30, 2024

Conditions

Unresectable Metastatic Colorectal Cancer

Interventions

DRUG

AK105 injection

AK105 is programmed death 1（PD-1） monoclonal antibody

DRUG

Anlotinib hydrochloride capsule

Anlotinib is small molecule multi-target tyrosine kinase inhibitor.

DRUG

CapeOX

CapeOX is Capecitabine+Oxaliplatin. Capecitabine is a kind of fluorouracil drug, and Oxaliplatin is a kind of platinum anticancer drug.

DRUG

Bevacizumab

Bevacizumab is a recombinant human monoclonal antibody.

Trial Locations (13)

130021

RECRUITING

Jilin Cancer Hospital, Changchun

150081

RECRUITING

Cancer Hospital Affiliated to Harbin Medical University, Harbin

200120

RECRUITING

Shanghai East Hospital, Shanghai

210029

RECRUITING

Jiangsu Province Hospital, Nanjing

214115

RECRUITING

Affiliated Hospital of Jiangnan University, Wuxi

225009

RECRUITING

Subei People's Hospital, Yangzhou

250117

RECRUITING

Shandong Cancer Hospital, Jinan

410031

RECRUITING

Hunan Cancer Hospital, Changsha

450062

RECRUITING

The First Affiliated Hospital of Henan University of Scinece and Technology, Luoyang

510180

RECRUITING

Affiliated Hospital of Guangdong Medical University, Zhanjiang

510655

RECRUITING

Sixth Affiliated Hospital of Sun Yat-sen University, Guangzhou

511316

RECRUITING

Sun Yixian Memorial Hospital,Sun Yat-sen University, Guangzhou

730013

RECRUITING

First Hospital of Lanzhou University, Lanzhou